Hong Kong-listed healthcare and biotech companies are accelerating weight-loss pipelines and artificial intelligence commercialization, while deploying hundreds of millions in share buybacks to stabilize market expectations, according to recent corporate filings and clinical registries.

Hengrui Pharmaceuticals (1276.HK)

Hengrui is accelerating its metabolic disease pipeline. The company initiated a Phase III clinical trial for its oral GLP-1/GIP weight-loss project in June 2026, according to clinical registry data. People familiar with the matter indicated the firm also secured a partnership with Bristol-Myers Squibb potentially worth over USD 1B. To boost market confidence, the company has executed share repurchases exceeding HKD 1B this year.

Innovent Biologics (1801.HK)

The company is targeting broader revenue scale following new approvals, with its self-developed IL-23p19 inhibitor cleared in Macau in June 2026. The firm reported 2025 total revenue of RMB 13.04B and a net income of RMB 1.72B. However, a proposal to expand the share issuance mandate faced 48.5% opposition at its June 24 shareholder meeting, highlighting significant divisions among institutional investors over capital allocation.

Yidu Tech (2158.HK)

In the deployment of healthcare AI, Yidu Tech has advanced 280 AI agents into clinical stages. At the Summer Davos forum in June 2026, company executives noted that data infrastructure, rather than singular models, dictates the upper limits of medical AI. Separately, its portfolio company Weijian International filed for a Hong Kong IPO on June 25, with prospectuses showing Yidu Tech holding a 4.71% stake.

3SBio (1530.HK)

3SBio has increased its capital market activities, spending approximately HKD 120M to repurchase 7.5M shares over two consecutive trading sessions in June 2026. On the clinical front, the company presented initial median progression-free survival data for its PD-1/VEGF bispecific antibody in first-line non-small cell lung cancer at the ASCO annual meeting. The company's chairman recently increased his equity stake.

Alibaba Health (0241.HK)

As a major internet healthcare platform, Alibaba Health is expanding its service boundaries through cross-sector partnerships. In June 2026, the company partnered with So-Young to launch post-procedure care packages aimed at standardizing aftermarket services. To retain core talent, the firm recently granted approximately 56.46M restricted share units.

CanSino Biologics (6915.HK)

Making headway in its vaccine export strategy, the company announced on June 26, 2026, that its quadrivalent meningococcal conjugate vaccine received national registration in Argentina, marking a further expansion of its international footprint.

Jacobson Pharma (2633.HK)

The company reported annual revenue of HKD 1.569B for the year ended March 2026, with net profit edging up to HKD 302M. It announced a final dividend of HKD 0.0475 per share, with the ex-dividend date set for September.

Mega Genomics (9637.HK)

Compliance and auditing issues continue to persist for the company. The firm delayed its 2024 annual results publication citing the need for additional time to complete audit procedures. Trading in its shares remains suspended, with no clear timetable for resumption.

Overall, while the sector faces isolated cases of trading suspensions and shareholder governance disputes, core constituents are hedging macro uncertainties by accelerating overseas clinical registrations and executing aggressive buybacks, with capital flows increasingly concentrating on leading firms.

This article does not constitute investment advice.